Patients at AHN’s Autoimmunity Institute participated in international clinical trial testing of Saphnelo™ (anifrolumab) – the first new biologic agent in more than a decade for the treatment of adult patients with moderate to severe lupus.
Allegheny Health Network
Advertisement
Articles by Allegheny Health Network
With Only 21 Facilities Achieving this Award Nationally, AGH Ranks Among the Most Elite Mitral Valve Programs in the Country
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD
2
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
3
Key Clinical Practice Pearls in Atopic Dermatitis, With Elaine Siegfried, MD
4
FAACT's “Food Allergies in the City” Offers Clinicians a Window into Patients' Daily Life
5